newsfilter
← Latest News
GlobeNewswire·

Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Strong balance sheet with successful completion of upsized $179.0 million initial public offering Treatment initiated in the first patient in an investigator-initiated basket trial of AlloNK® exploring multiple